Artificial intelligence could help treat mesothelioma in the future. Researchers in Scotland have been developing a prototype imaging system to help with diagnostics and therapeutics for the treatment of mesothelioma. It is being developed at the University of Glasgow and Canon Medical Research Europe. The artificial intelligence uses computer software[…]
Novel Treatments & Drugs
A Combination of Tremelimumab and Durvalumab Can Extend Mesothelioma Survival
An Italian study has found that the combination of two immunotherapy drugs can create a long-term survival in mesothelioma patients. The two drugs, tremelimumab and durvalumab, were just given orphan drug status to treat liver cancer in the last year. The best results in the mesothelioma study were seen in[…]
An Inhaled Vaccine Could Potentially Help Mesothelioma Patients in the Future
An inhaled vaccine could be used for mesothelioma treatment soon. Research done at MIT is showing that the inhaled vaccine can trigger an immune response for certain infections and possibly lung-based cancers. This is great news for people with mesothelioma. Lung infections typically start on mucosal membranes, so researchers created[…]
Second Mesothelioma Surgeries Can Help Extend Lives and Improve Quality of Life of Patients
Surgery can be hard on the body, but it can help some mesothelioma patients if done a second time. People could still have a good quality of life and even an extended survival if they undergo the aggressive surgery. This surgery is not common and would not be recommended for[…]
ONCOS-102 Improves Pleural Mesothelioma Survival
There is promising new data from the makers of ONCOS-102 that shows that the treatment can help improve the long-term survival of mesothelioma patients. ONCOS-102 was recently given Fast-Track approval by the FDA to speed up its development. ONCOS-102 is a modified adenovirus that infects cancer cells. The new mesothelioma[…]
The ONCOS-102 Vaccine Was Just Given the Fast-Track Designation
The ONCOS-102 immunotherapy vaccine was given the Fast-Track Designation, which will speed up regulatory approval. The vaccine is used to treat mesothelioma and other cancers. Targovax, which developed the treatment, is taking this as an endorsement from the FDA. Targovax is a small biotech company that mainly works with oncolytic[…]
SMART Mesothelioma Procedure Could Extend the Lives of Certain Mesothelioma Patients
Accelerated high dose radiation before surgery created a 65.9 month survival for mesothelioma patients. They were part of a clinical trial in Toronto at the Princess Margaret Cancer Center. The study is named SMART, an acronym for Surgery for Mesothelioma After Radiation Therapy. There were 96 patients who were treated[…]
The ONCOS-102 Vaccine is Still Showing Promising Results
The ONCOS-102 immunotherapy vaccine is still showing promising results. Information from November shows when patients take the treatment with chemotherapy, it helped patients survive a minimum of 18.2 months. The median overall survival was four months better in the experimental group compared to the control group. Targovax, the maker of[…]
New Immuno-Radiology Treatment Being Tested on Mesothelioma
Mesothelioma is a cancer with a bad prognosis that is primarily caused by asbestos exposure. There is no cure for mesothelioma, so people diagnosed with the disease do not have a great chance of living long past their diagnoses. Clinical trials are people’s best chance of finding a better treatment[…]
Mesothelioma Trial Involving UV1 Cancer Vaccine and Immunotherapy
A new mesothelioma clinical trial is taking place in Oslo, Norway. The trial is looking at the UV1 cancer vaccine alongside immunotherapy. The vaccine is a peptide-based drug that activates a T-cell response, allowing the immunotherapy drugs to work better. This will be the first time that UV1 is being[…]
Skip to content